In 2013, two discoveries—that alkylating agent chemotherapy prolongs survival when added to radiotherapy for patients with anaplastic oligodendroglial tumours with 1p19q codeletion, and that bevacizumab prolongs progression-free survival in patients with newly diagnosed glioblastoma—have dominated debate in neuro-oncology. These findings could help to define new standards of care in malignant glioma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program
Acta Neuropathologica Open Access 19 August 2019
-
Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1)
BMC Cancer Open Access 05 October 2016
-
Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas
Journal of Experimental & Clinical Cancer Research Open Access 26 October 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Weller, M. et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 14, e370–e379 (2013).
Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425–437 (2012).
Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–467 (2013).
Van den Bent, M. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 31, 344–350 (2013).
Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337–343 (2013).
Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874–5880 (2009).
Wick, W. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81, 1515–1522 (2013).
Chinot, O. et al. Bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. (in press).
Gilbert, M. R. et al. Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). N. Engl. J. Med. (in press).
Wefel, J. S. et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 13, 660–668 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Weller has received research grants from Isarna Therapeutics, Bayer, Merck Serono, MSD and Roche, and honoraria for lectures or advisory boards from Isarna Therapeutics, MagForce, Merck Serono, MSD and Roche. He was the principal investigator of phase II or phase III trials investigating temozolomide (MSD) in newly diagnosed anaplastic glioma and glioblastoma, as well as recurrent glioblastoma and bevacizumab in glioblastoma. W. Wick has received consulting and lecture fees from MSD, Roche and MagForce, and has received research support from Apogenix, Boehringer Ingelheim, Eli Lilly, MSD and Roche. He serves on the Steering Committee of the AVAglio trial involving bevacizumab in glioblastoma and has been lead investigator in glioma trials involving temozolomide, bevacizumab, enzastaurin and APG101.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Weller, M., Wick, W. Improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol 10, 68–70 (2014). https://doi.org/10.1038/nrneurol.2013.268
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.268
This article is cited by
-
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program
Acta Neuropathologica (2019)
-
MicroRNA-211 expression is down-regulated and associated with poor prognosis in human glioma
Journal of Neuro-Oncology (2017)
-
Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1)
BMC Cancer (2016)
-
Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas
Journal of Experimental & Clinical Cancer Research (2015)
-
Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors
Journal of Neuro-Oncology (2015)